Aena SA (0R4Y) Gets a Hold from Citi
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Khetan is ranked #5923 out of 9595 analysts.
Aena SA has an analyst consensus of Hold, with a price target consensus of €223.35.
Based on Aena SA's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of €1.32 billion and a net profit of €301.31 million. In comparison, last year the company earned a revenue of €1.22 billion and had a net profit of €261 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Astera Labs Announces Third Quarter 2025 Financial Conference Participation
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in financial conferences for the third quarter 2025. Deutsche Bank 2025 Technology Conference on Aug. 28, 2025. Astera Labs' presentation is scheduled for 12:30 pm PT. Citi's 2025 Global TMT Conference on Sept. 4, 2025. Astera Labs' presentation is scheduled for 8:50 am ET. A webcast of each session will be made available on Astera Labs' investor relations website at About Astera Labs Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at IR CONTACT: Leslie
Business Wire
2 hours ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
Business Insider
3 hours ago
- Business Insider
Trump Trade: Lutnick says Intel must give stake to government
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump with this daily recap compiled by The Fly: Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. INTEL STAKE: Commerce Secretary Howard Lutnick said that in return for CHIPS Act funds, Intel (INTC) must give the U.S. government an equity stake. The comments were made while Lutnick was being interviewed on CNBC's 'Squawk on the Street.' BOND SPREE: President Donald Trump has bought hundreds of bonds since he returned to office, including those sold by U.S. companies affected by federal policy changes he's championed, Bloomberg reports. The bonds, which total at least $103.7M, include municipal bonds and corporate debt from companies such as Qualcomm (QCOM), Home Depot (HD), and Meta Platforms (META), according to the report, which adds that the investments are part of Trump's continued pursuit of wealth accumulation while in office. TARIFF REVENUE TO OFFSET OBBB: S&P Global on Tuesday said it expects tariff-related revenue for the federal government to offset the impact of Trump's 'One Big Beautiful Bill,' leading the agency to leave the U.S.′ credit rating unchanged. MUSK PUMPS BRAKES ON THIRD PARTY PLANS: Tesla (TSLA) CEO Elon Musk is quietly pumping the brakes on plans to start a third political party, the America Party, with a desire to focus on his companies, The Wall Street Journal's Brian Schwartz reports. Musk is wary of alienating Republicans and wants to maintain ties with Vice President JD Vance, a potential 2028 presidential candidate, according to people with knowledge of his plans. The Tesla CEO's team canceled a meeting with a third-party campaign-organizing group, according to the report.
